The first clinical trial investigating NKG2D-CAR-NK therapy in relapsed/refractory MM is currently underway, aiming to evaluate safety, tolerability, and early efficacy endpoints (NCT06379451). Here, KLRK1 is linked to Miyoshi myopathy.